<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958122</url>
  </required_header>
  <id_info>
    <org_study_id>HS-21-00288</org_study_id>
    <nct_id>NCT04958122</nct_id>
  </id_info>
  <brief_title>Cefixime Clinical Trial</brief_title>
  <official_title>Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in&#xD;
      the treatment of syphilis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, multisite, open-label, non-inferiority clinical trial to evaluate&#xD;
      the effectiveness of cefixime (400mg orally, twice a day, for 10 days) compared to benzathine&#xD;
      penicillin G (2.4 million units, intramuscularly) in patients with and without HIV infection.&#xD;
      In total, 400 participants with early syphilis will be enrolled from 9 clinical sites in the&#xD;
      U.S. and Peru. Participants will participate in follow-ups to monitor clinical outcomes and&#xD;
      serological response (RPR titer) every 3 months for 9 months. Study findings may identify an&#xD;
      efficacious alternative syphilis treatment to penicillin, effective for people living with&#xD;
      HIV infection, to help address the crisis of penicillin shortages and offer options for those&#xD;
      with penicillin allergy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of cefixime participants with a 4-fold decrease or greater in the serum RPR titer 3 or 6 months after treatment completion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Syphilis</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Cefixime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral cefixime 400mg, taken twice a day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzathine Penicillin G</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intramuscular injection of 2.4 million units of benzathine penicillin G</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefixime 400mg</intervention_name>
    <description>Oral cefixime 400 mg, one capsule, twice a day for 10 days</description>
    <arm_group_label>Cefixime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benzathine penicillin</intervention_name>
    <description>Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU</description>
    <arm_group_label>Benzathine Penicillin G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8&#xD;
             within 3 weeks prior to enrollment&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Individuals with HIV infection must be on treatment for HIV infection and&#xD;
             virologically suppressed (viral load &lt;200 copies/mL) or have a CD4 count ≥ 350&#xD;
             cells/mm3 according to most recent labs before study enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or a positive pregnancy test on the day of enrollment&#xD;
&#xD;
          -  Patients showing signs and symptoms of neurosyphilis&#xD;
&#xD;
          -  Serofast RPR titer, defined as persistently positive RPR titer without more than&#xD;
             4-fold (2-titer level) change for 12 months or greater&#xD;
&#xD;
          -  Recent (within the past 7 days) or concomitant antimicrobial therapy with activity&#xD;
             against syphilis, namely azithromycin, doxycycline, ceftriaxone, or other beta-lactam&#xD;
             antibiotics (e.g. amoxicillin)&#xD;
&#xD;
          -  Individuals with HIV infection who report HIV treatment interruption for more than 4&#xD;
             weeks since their most recent viral load or CD4 test&#xD;
&#xD;
          -  Self-reported allergy to cephalosporins or penicillin&#xD;
&#xD;
          -  Unwilling or unable to attend follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey D Klausner</last_name>
    <phone>(415) 876-8901</phone>
    <email>jdklausner@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey D Klausner, MD</last_name>
      <phone>415-876-8901</phone>
      <email>jdklausner@med.usc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Jeffrey Klausner</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Cefixime</keyword>
  <keyword>Treponema pallidum</keyword>
  <keyword>Penicillin</keyword>
  <keyword>Early Syphilis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Cefixime</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

